Research Article| Volume 45, ISSUE 7, P1153-1161, May 2009

Download started.


Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer

Published:December 29, 2008DOI:


      The combination of trabectedin (T) and doxorubicin (D) was brought into clinical development in soft tissue sarcoma (STS) and advanced breast cancer (ABC) because of its in vitro and in vivo additive anti-tumour effect, the fact that there are no overlapping toxicities and the anti-tumour activity of T in those tumours. Feasibility and anti-tumour activity of T+D administered every 3 weeks were evaluated in 38 patients (STS=29, ABC=9) untreated for advanced disease. D was given at 60 mg/m2 and T at escalating doses from 600 to 800 μg/m2, which was the maximum tolerated dose due to dose-limiting febrile neutropenia and asthenia. The recommended dose - given to 18 patients in total - was 700 μg/m2 T with 60 mg/m2 D. The pharmacokinetic profile of T and D at cycle 1 was analysed in 20 patients. The most common toxicities included a severe but reversible ASAT/ALAT increase (94%), nausea/vomiting, neutropenia, asthenia/fatigue, stomatitis. Partial response and stable disease were assessed in 18% and 56% of STS patients and in 55% and 33% of ABC patients. No pharmacokinetic interaction between T and D was observed. The lack of cumulative toxicity and related complications and the promising activity in STS support further development of T+D.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Pommier Y.
        • Kohlhagen G.
        • Bailly C.
        • Waring M.
        • Mazumder A.
        • Kohn K.W.
        DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata.
        Biochemistry. 1996; 35: 13303-13309
        • Moore II, B.M.
        • Seaman F.C.
        • Hurley L.H.
        NMR-based model of an ecteinascidin 743-DNA adduct.
        J Am Chem Soc. 1997; 119: 5475-5476
        • Soares D.G.
        • Escargueil A.E.
        • Poindessous V.
        • et al.
        Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
        Proc Natl Acad Sci USA. 2007; 104: 13062-13067
        • Tavecchio M.
        • Simone M.
        • Erba E.
        • et al.
        Role of homologous recombination in trabectedin-induced DNA damage.
        Eur J Cancer. 2008; 44: 609-618
        • Damia G.
        • D’Incalci M.
        Targeting DNA repair as a promising approach in cancer therapy.
        Eur J Cancer. 2007; 43: 1791-1801
        • Minuzzo M.
        • Marchini S.
        • Broggini M.
        • Faircloth G.T.
        • D’Incalci M.
        • Mantovani R.
        Interference of transcriptional activation by the anti-neoplastic drug ET-743.
        PNAS. 2000; 97: 6780-6784
        • Jin S.
        • Gorfajn B.
        • Faircloth G.
        • Scotto K.W.
        Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation.
        Pro Natl Acad Sci USA. 2000; 97: 6775-6779
        • Minuzzo M.
        • Ceribelli M.
        • Pitarque-Martì M.
        • et al.
        Selective effects of the anti-cancer drug Yondelis (ET-743) on cell-cycle promoters.
        Mol Pharmacol. 2005; 68: 1496-1503
        • Brennan M.F.
        • Casper E.S.
        • Harrison L.B.
        Soft tissue sarcoma.
        in: Cancer: principles and practice of oncology. vols. 1738–1788. Lippincott-Raven Publisher, Philadelphia, New York1997
        • O’Byrne K.
        • Steward W.P.
        The role of chemotherapy in the treatment of adult soft tissue sarcomas.
        Oncology. 1999; 56: 13-23
        • Bramwell V.H.
        • Anderson D.
        • Charette M.L.
        Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-analysis and clinical practice guideline.
        Sarcoma. 2000; 4: 103-112
        • Demetri G.D.
        • Elias A.D.
        Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implication for decision making in the clinic.
        Hemat Oncol Clinics of North America. 1995; 9: 765-785
        • Antman K.
        • Crowley J.
        • Balcerzak S.P.
        • et al.
        An Intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcoma.
        J Clin Oncol. 1993; 11: 1276-1285
        • Edmonson J.H.
        • Ryan L.M.
        • Blum R.H.
        • et al.
        Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
        J Clin Oncol. 1993; 11: 1269-1275
        • Patel S.R.
        • Vadhan-Raj S.
        • Burgess M.A.
        • et al.
        Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas.
        Am J Clin Oncol. 1998; 21: 317-321
        • Elias A.D.
        High-dose therapy for adult soft tissue sarcoma: dose response and survival.
        Sem Oncol. 1998; 25: 19-23
        • Le Cesne A.
        • Blay J.Y.
        • Judson I.
        • et al.
        Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organization for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.
        J Clin Oncol. 2005; 23: 5276
        • Garcia-Carbonero R.
        • Stupko J.G.
        • Maki R.G.
        • et al.
        Ecteinascidin-743 (ET-743) for chemotherapy-naïve patients with advanced soft tissue sarcomas: multicenter phase II and Pharmacokinetic study.
        J Clin Oncol. 2005; 23: 5420-5423
        • Verweij J.
        Ecteinascidin-743 (ET-743): early test of effective treatment in soft tissue sarcomas?.
        J Clin Oncol. 2005; 23: 5484-5492
        • Meco D.
        • Colombo T.
        • Ubezio P.
        • et al.
        Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies.
        Cancer Chemother Pharmacol. 2003; 52: 131-138
        • Zelek L.
        • Yovine A.
        • Brain E.
        • et al.
        A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer.
        Br J Cancer. 2006; 94: 1610-1614
        • Gianni L.
        • Vigano L.
        • Locatelli A.
        • et al.
        Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer.
        J Clin Oncol. 1997; 15: 1906-1915
        • Grasselli G.
        • Viganò L.
        • Capri G.
        • et al.
        Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer.
        J Clin Oncol. 2001; 19: 2222-2231
        • Takahashi N.
        • Li W.W.
        • Banerjee D.
        • Scotto K.W.
        • Bertino J.R.
        Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells.
        Clin Cancer Res. 2001; 7: 3251-3257
        • van Kesteren Ch.
        • de Vooght M.M.
        • López-Lázaro L.
        • et al.
        Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study.
        Anticancer Drugs. 2002; 13: 381-393
        • Therasse P.
        • Arbuck S.G.
        • Eisenhauer E.A.
        • et al.
        New guidelines to evaluate the response to treatment in solid tumors.
        J Natl Cancer Inst. 2000; 92: 205-216
        • Rosing H.
        • Hillebrandt M.J.
        • Jimeno J.M.
        • et al.
        Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
        J Mass Spectrom. 1998; 33: 1134-1140
        • Grosso F.
        • Jones R.L.
        • Demetri G.D.
        • et al.
        Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.
        Lancet Oncol. 2007; 8: 595-602
        • Blay J.Y.
        • von Mehren M.
        • Samuels B.L.
        • et al.
        Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.
        Clin Cancer Res. 2008; 14: 6656-6662
        • Sessa C.
        • De Braud F.
        • Perotti A.
        • et al.
        Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.
        J Clin Oncol. 2005; 23: 1867-1874
        • Kanzaki A.
        • Takebayashi Y.
        • Ren X.Q.
        • et al.
        Overcoming multidrug drug resistance in P-Glycoprotein/MDR1-overexpressing cell lines by Ecteinascidin 743.
        Mol Cancer Ther. 2002; 1: 1327-1334
      1. von Mehren M, Schilder RJ, Cheng JD et al. A phase I study of the safety and pharmacokinetics of trabectedin in combinations with pegylated liposomal doxorubicin in patients with advanced malignancies. Ann Oncol 2008, May 22.

        • Twelves C.J.
        • Dobbs N.A.
        • Aldhous M.
        • et al.
        Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer.
        Cancer Chemother Pharmacol. 1991; 28: 302-307
      2. Messersmith WA, Jimeno A, Ettinger D, et al. Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol 2008 Apr 1 (Epub ahead of print).